NEW YORK (GenomeWeb News) – Cancer diagnostics services firm BioTheranostics today announced a contract with preferred provider organization Three Rivers Provider Network.

The contract covers the San Diego firm's testing services, including CancerType ID for diagnosing metastatic cancer, and Breast Cancer Index for predicting the risks of recurrence of early stage, estrogen receptor-positive breast cancer. The agreement makes BioTheranostics' tests available to an additional 15 million covered lives in the US, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.